/PRNewswire/ Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the.
Precigen, Inc. (NASDAQ:PGEN – Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 13,690,000 shares, an increase of 39.4% from the August 15th total of 9,820,000 shares. Based on an average trading volume of 1,670,000 shares, the […]
StockNews.com started coverage on shares of Precigen (NASDAQ:PGEN – Free Report) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock. A number of other equities analysts also recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Precigen in […]
StockNews.com assumed coverage on shares of Precigen (NASDAQ:PGEN – Free Report) in a research report sent to investors on Tuesday. The firm issued a sell rating on the biotechnology company’s stock. Several other brokerages have also issued reports on PGEN. HC Wainwright restated a buy rating and issued a $6.00 target price on shares of […]